Heparin Market By Product (Weight Heparin, Unfractionated Heparin, Ultra-Low Molecular, and Low Molecular Weight Heparin), Application (Coronary Artery Disease, Atrial Fibrillation, Venous Thromboembolism, and Others), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Drug Stores & Retail Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

The Global Heparin Market size is expected to be worth around USD 13.0 Billion by 2032 from USD 8.3 Billion in 2022, growing at a CAGR of 4.70% during the forecast period from 2022 to 2032.

Heparin, commonly referred to as Unfractionated Heparin (UFH), is a naturally occurring glycosaminoglycan. In medicine, it serves as an anticoagulant (blood thinner). Treatment of unstable angina & heart attacks benefits greatly from it. This is injected directly into a vein or subcutaneously. Acute coronary syndrome, pulmonary embolism, deep-vein thrombosis, hemofiltration, atrial fibrillation, and cardiopulmonary bypass are just a few of the conditions it is utilized to treat. The execution of major orthopedic surgeries like knee and hip replacements also makes use of it.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• Market Size: Heparin’s market is hugely diverse due to the widespread usage of its-based medications in healthcare settings worldwide.
• Surgical and Medical Applications of Heparin: Heparin can be utilized both during surgical procedures (for instance heart surgeries) as well as treating conditions like deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Biotechnology Innovations: Ongoing biotech research and advancements aim to further the effectiveness and safety of heparin.
• Anticoagulation Reversal: Heparin’s effects can be reversed with protamine sulfate to provide a means for managing excessive anticoagulation in clinical settings.
• Oversight by Regulators: Regulating authorities such as the FDA oversee the quality and safety of heparin products to protect patients.
• Economic Factors: Heparin-based medications play a critical role in healthcare budgets; pricing could have significant ramifications on pricing decisions in this market.Market Size: Heparin’s market presence can only increase given their widespread application across healthcare settings.

Product Analysis

The Low Molecular Weight Heparin Segment Accounted for the Largest Market Share in Product Type

Based on product types, the global heparin market is segmented into weight heparin, unfractionated heparin, ultra-low molecular, and low molecular weight heparin.

Among these products, the low molecular weight heparin occupied the largest market share and is anticipated to stay in the forecast period. Because heparin’s market expansion is influenced by several significant variables, including its prolonged & more predictable functioning than UFH, ease of self-administration at home through subcutaneous injection, which decreases hospital stays, and the lack of a daily blood checking requirement.

Application Analysis

The Coronary Artery Disease Segment Accounted for the Largest Market Share in Application Type

Based on application types, the global heparin market is segmented into coronary artery disease, atrial fibrillation, venous thromboembolism, and others.

Among these applications, the largest market share was occupied by coronary artery disease and is anticipated to stay in the forecast period. From 2023 to 2032, the global venous thromboembolism market is anticipated to experience rapid growth.

Rising knowledge of thrombosis is one of the major factors propelling the segment’s growth. For instance, Haemostasias, Inc., and the Thrombosishas started an online site to educate patients about thrombosis.

Distribution Channel Analysis

The Hospital Pharmacies Segment Accounted for the Largest Market Share in Distribution Channel Type

Based on distribution channel types, the global heparin market is segmented into online pharmacies, hospital pharmacies, and drug stores & retail pharmacies. Hospital pharmacies occupy the largest market share among these distribution channels and are anticipated to stay in the forecast period.

Because the elevated services, easy availability of pharmaceuticals, and a growing dependence on medical practitioners for heparin recommendations all contribute to the growth of the hospital segment.

Key Market Segments

Product

• Weight Heparin
• Unfractionated Heparin
• Ultra-Low Molecular
• Low Molecular Weight Heparin

Application

• Coronary Artery Disease
• Atrial Fibrillation
• Venous Thromboembolism
• Others

Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies

Drivers

Increased incidence of cardiovascular disorders is expected to drive the Market growth.

The increased incidence of cardiovascular disorders, which will increase demand for these products, is a significant driving force affecting the global market. In the upcoming years, it is anticipated that nearly all types of cardiovascular disorders, including atrial fibrillation, strokes, venous thromboembolism, and heart-related problems, will continue to rise.

These patterns and figures show that sizable patient populations are present worldwide, impacting the high demand for these goods. Additionally, the market will rise as patients become more aware of how effective these medications are at treating different heart ailments.

Robust Adoption of the Product in Various Applications to Stimulate Market Growth

Another important element projected to fuel the global market expansion is the effectiveness of these medications as anticoagulants. Indisputable elements like technological developments and the introduction of novel goods are also projected to significantly fuel the growth of the global market throughout the forecast period.

The steady increase in the consumption of these medications has sped up efforts to create LMWH. Furthermore, other forms like Ultra-low Molecular Weight Heparin have emerged due to technical breakthroughs (ULMWH). As a result, these elements are anticipated to favorably affect the market over the forecast period.

Restraints

Lack of Raw Materials and Increased Prices Will Limit Market Growth

The limited raw materials availability by the Chinese for producing products based on porcine is one of the major restraints on expanding the worldwide market. African Swine Fever (ASF), a lethal disease for swine, has recently caused numerous outbreaks in China, which has resulted in the widespread slaughter of pigs to manage outbreaks.

As a result, these elements may contribute to the ongoing scarcity of raw materials needed to produce goods. The second factor limiting the market’s growth in the coming years is the higher prices involved with LMWH, which can prevent it from being more widely adopted in emerging markets.

Trends

Throughout the Forecast Period, Low Molecular Weight Heparin (Lmwh) is Anticipated to Hold a Sizable Market Share

Throughout the forecast period, Low Molecular Weight Heparin (LMWH) is anticipated to hold a sizable market share. Low molecular weight heparin (LMWH), an anticoagulant, is injected subcutaneously or intravenously. Examples include enoxaparin and dalteparin, which function by triggering antithrombin III, which then renders factor Xa and thrombin inactive to induce their action.

Regional Analysis

North America Was the Market Leader and Generated the Highest Revenue Share

North America was the dominant region and generated the highest revenue share. The increase in cardiovascular diseases and accidents brings this on. Additionally, variables contributing to the region’s high percentage include rising healthcare spending and patient understanding in this area.

Every year, one in four Americans in the US pass away from cardiovascular disease, making it one of the most common reasons of death in the nation.

Asia Pacific is Expected to Have the Market’s Fastest Growth

The market is anticipated to grow fastest in the Asia-Pacific heparin market over the anticipated period. Some of the main drivers of the expansion are the increasing geriatric population, the large population suffering from chronic diseases & developing economy.

Additionally, Asia-Pacific is the region that supplies the most API and crude heparin. This benefits regional businesses like Pharmax Lifesciences. Generic versions of medications whose patents have expired are produced locally at a reasonable price.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

With the presence of many local and regional players, the market for Global Heparin Market is fragmented. Market players are subject to intense competition from top players, particularly those with strong brand recognition and high distribution networks. Companies have gained various expansion strategies, such as partnerships and product launches, to stay in the competition.

Listed below are some of the most prominent bio-based surface disinfectant industry players.

Market Key Players

• GlaxoSmithKline plc
• Aspen Pharmacare Holdings Limited
• Braun Medical Inc.
• Baxter International Inc.
• Cipla Ltd.
• Reddy’s Laboratories Ltd.
• Hoffmann-La Roche Ltd.
• Fresenius SE & Co. KGaA
• Leo Pharma A/S
• Novartis AG
• Pfizer Inc.
• OPOCRIN SPA.
• Reddy’s Laboratories Ltd.
• SARIA International GmbH
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• United Biotech (P) Ltd.
• Viatris Inc.
• Bio-pharma Co., ltd.
• Other Key Players.

Recent Development

• In March 2022, To expand its distribution network, Hepalink Group announced that the APIs for heparin sodium & enoxaparin sodium had been approved in India.
• In April 2021, Fresenius Kabi announced the availability of 2 new heparin sodium presentations in cozy, ready-to-use Freeflex IV bags inside the United States.
• In February 2020, Meitheal Pharmaceuticals announced that the FDA had authorized plans for future facility growth and additional manufacturing capacity for producing Heparin Sodium Injection.

Report Scope